Aldevron Breakthrough Blog
Pressure Reshaping the Development Process
November 18, 2026 by Aldevron
Connecting workflows. Reducing risk. Accelerating development.
Cell and gene therapy developers are making manufacturing decisions earlier than ever—and there is a good reason for that. Once a program is moving, changing an editing reagent, construct, or formulation can create comparability work, add risk, and slow the path to the clinic.
We heard that concern repeatedly at Meeting on the Mesa in Phoenix. Customers want confidence that the materials they use in discovery can move into clinical manufacturing without a disruptive redesign. They are also looking for faster custom constructs, clearer quality documentation, scalable production, and practical help with cost-of-goods and commercialization planning.
For emerging biotechnology companies, the pressure is especially real. Funding remains tight, so teams are focusing resources on their strongest programs. They cannot afford avoidable delays caused by fragmented suppliers, unclear specifications, or a manufacturing strategy that was not designed with the destination in mind.
A connected research-to-GMP approach can offer a better path. When guide design, gene-editing reagents, mRNA, plasmid templates, and GMP supply are planned as one workflow, teams can reduce handoffs and prepare for scale with more confidence. It also becomes easier to align analytical methods, quality expectations, and regulatory documentation early.
The point is not simply to manufacture more material. It is to build a development path that preserves performance while becoming more controlled, reproducible, and commercially realistic at every stage.
Early alignment also helps scientific, quality, regulatory, and commercial teams make better decisions together. Shared specifications and clear transition points make tradeoffs easier to evaluate, supply needs easier to anticipate, and potential partners easier to assess.
The biggest takeaway from the event? Scalability is not something to solve after proof of concept. It is a design requirement from day one. Organizations that connect early research choices to clinical and commercial needs will be better positioned to move promising therapies forward with speed and confidence.
- Have questions on this topic? Contact Us
- Learn more about the modalities we support
- Have an idea for a topic? Let us know!